Patient-specific, high-sensitivity spectral CT for assessment of pancreatic cancer

用于评估胰腺癌的患者特异性高灵敏度能谱 CT

• 批准号: 10491791
• 负责人: Jianan Grace Gang
• 金额: $ 61.38万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-22 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10491791
• 关键词: 3D Print; Achievement; Algorithms; Anatomy; Automobile Driving; Biological Markers; Biological Products; Calibration; Characteristics; Clinical; Clinical Trials; Complement; Complex; Computed Tomography Scanners; Computer software; Contrast Media; Data; Dependence; Detection; Diagnosis; Diagnostic; Disease; Disease Management; Enhancing Lesion; Evaluation; Functional Imaging; Goals; Hybrids; Image; Imaging Techniques; Iodine; Joints; Lead; Lesion; Magnetic Resonance Imaging; Malignant neoplasm of pancreas; Measurement; Measures; Methods; Modeling; Morphology; Noise; Organ; Outcome; Pancreas; Patients; Pattern; Performance; Perfusion; Physics; Property; Protocols documentation; Radiation Dose Unit; Radiation exposure; Reproducibility; Roentgen Rays; Selection Bias; Shapes; Source; Staging; System; Technology; Texture; Theoretical model; Tissues; Treatment Efficacy; Tweens; Vendor; Visualization; Work; X-Ray Computed Tomography; artificial intelligence algorithm; attenuation; base; clinical application; clinical decision-making; clinical translation; contrast enhanced; denoising; design; detector; fluorodeoxyglucose positron emission tomography; imaging approach; imaging biomarker; imaging modality; imaging system; improved; next generation; novel; novel therapeutics; perfusion imaging; predictive modeling; public health relevance; quantitative imaging; response; spectrograph; technology development; tumor; tumor microenvironment

Abstract. The proposed project concentrates on technology developments to enable high sensitivity, bias-tolerant spectral CT for accurate quantitation of iodine concentration. Spectral CT has the potential of providing true quantitative information of tissue composition and provides an avenue for combined functional and structural imaging. High- sensitivity spectral CT accommodates anatomical sites that are traditionally hard to image, and reliable meas- urements of iodine perfusion allow additional quantitative measures such as tissue texture to aid diagnosis and clinical decision making. In the case of pancreatic cancer, the complex tumor microenvironment and the conse- quential poor perfusion characteristics lead to difficulty in diagnosis, staging, and treatment assessment. The need for visualizing low-enhancing lesions and the benefit of extracting quantitative information directly from image data strongly motivate a high-sensitivity imaging modality for reproducible iodine measurements. The need for visualizing low-enhancing lesions and the benefit of extracting quantitative information directly from image data strongly motivate a high-sensitivity imaging modality for reproducible iodine measurements. How- ever, state-of-the-art spectral CT presents large quantitation bias, i.e., inaccuracies in measured iodine concen- tration compared to the truth. We identify three major sources that contribute to quantitation bias: imaging system (e.g., spectrum mismatch), post-processing (e.g., biased estimator), and patient (scatter, beam hardening). The bias effect in current spectral CT cannot be fully eliminated by increasing radiation exposure, and has complex dependencies on the imaging system, imaging techniques, patient habitus, and processing algorithms. This in- accuracy is a major impediment to pancreatic cancer management and quantitative applications in general. The overall goal of this proposal is to develop robust, high-sensitivity spectral CT solutions that will enhance sensi- tivity and reduce variability in iodine quantitation, which in turn enables accurate, high-performance spectral biomarkers for disease management. The following specific aims will be pursued: (1) to develop an end-to-end, modular theoretical model for robust spectral CT design and optimization, (2) to develop bias-tolerant processing pipeline, and (3) to implement and evaluate high performance, hybrid spectral CT solutions on an experimental CT bench. Completion of the proposed efforts enables robust, high sensitivity spectral CT for improved tumor detection and characterization through accurate, high performance spectral biomarkers. Vendor- and spectral technology-independent outcomes of the proposal include: optimized, patient-specific protocols; post-processing pipelines that are robust against quantitative bias and variability; and the next generation spectral CT system designs for enhanced iodine quantitation. Achievements from the proposed project will improve sensitivity and quantitation accuracy of iodinated contrast media in spectral CT which enables quantitative diagnostics and treatment assessment using robust iodine biomarkers across a broad range of clinical applications.

抽象。 拟议的项目集中在技术开发，以实现高灵敏度，偏压容忍光谱 CT用于准确定量碘浓度。能谱CT有潜力提供真正的定量 组织组成的信息，并提供了一种途径，结合功能和结构成像。高- 灵敏度光谱CT可适应传统上难以成像的解剖部位， 碘灌注的快速测量允许额外的定量测量，例如组织纹理，以帮助诊断， 临床决策在胰腺癌的情况下，复杂的肿瘤微环境和结果- 连续的灌注不良特征导致诊断、分期和治疗评估的困难。的 需要对低增强病变进行可视化，以及直接从 成像数据强烈地激发了用于可再现碘测量的高灵敏度成像模态。的 需要对低增强病变进行可视化，以及直接从 成像数据强烈地激发了用于可再现碘测量的高灵敏度成像模态。怎么-- 然而，现有技术的光谱CT呈现出大的定量偏差，即，碘浓度测量不准确， 与真相相比，我们确定了三个主要来源，有助于定量偏差：成像系统 (e.g.,频谱失配），后处理（例如，有偏估计器）和患者（散射、射束硬化）。的 当前光谱CT中的偏置效应不能通过增加辐射曝光来完全消除，并且具有复杂的 依赖于成像系统、成像技术、患者体质和处理算法。这在- 准确性通常是胰腺癌管理和定量应用的主要障碍。的 该提案的总体目标是开发强大的高灵敏度光谱CT解决方案， 提高了碘定量的灵敏度，降低了碘定量的变异性，从而实现了准确、高性能的光谱分析。 用于疾病管理的生物标志物。将追求以下具体目标：（1）开发一个端到端， 模块化理论模型，用于稳健的光谱CT设计和优化，（2）开发偏差容限处理 流水线，以及（3）在实验平台上实施和评估高性能混合光谱CT解决方案 CT台。完成拟议的努力，使强大的，高灵敏度光谱CT改善肿瘤 通过准确、高性能的光谱生物标志物进行检测和表征。供应商和光谱 该提案的技术独立成果包括：优化的患者特定协议;后处理 对定量偏差和可变性具有鲁棒性的管道;以及下一代光谱CT系统 增强碘定量的设计。拟议项目的成果将提高敏感性， 光谱CT中碘化造影剂的定量准确性，可实现定量诊断， 在广泛的临床应用中使用稳健的碘生物标志物进行治疗评估。